February 1, 2013

CURRICULUM VITAE

Jay L. Hess M.D., Ph.D., M.H.S.A.

PERSONAL DATA Work Address: University of Michigan Health System 1500 East Medical Center Drive, 5240 MS1 Ann Arbor, MI 48109 CURRENT POSITION: Carl V. Weller Professor and Chair, Department of Pathology Professor of Internal Medicine Director of Clinical Laboratories

Director, Division of Sponsored Research, Department of Pathology University of Michigan Health System, Ann Arbor, MI

EDUCATION 1982 B.A. Johns Hopkins University (Biophysics) 1989 M.D. Johns Hopkins University School of Medicine 1989 Ph.D. Johns Hopkins University School of Medicine (Biochemistry, Cellular and Molecular Biology)

2002 Certificate Wharton Management Program, The Wharton School of the University of Pennsylvania (eight course certificate program in business administration)

2012 M.H.S.A. Department of Health Management and Policy, University of Michigan School of Public Health (19 course master’s degree program in public health/healthcare administration)

POSTGRADUATE TRAINING 1989-1991 Resident in Anatomic Pathology, Brigham and Women’s Hospital, Boston, MA 1989-1993 Clinical Fellow in Pathology, Harvard Medical School, Boston, MA 1991-1992 Fellow in Hematopathology, Brigham and Women’s Hospital, Boston, MA 1992-1993 Chief Resident and Fellow in Surgical Pathology, Brigham and Women’s Hospital, Boston, Massachusetts and Memorial Sloan-Kettering Cancer Center, New York, NY

FACULTY APPOINTMENTS 7/1/93-6/30/99 Assistant Professor of Pathology, Washington University School of Medicine, St. Louis, MO 7/1/99-6/30/00 Lecturer in Pathology and Laboratory Medicine University of Pennsylvania School of Medicine, Philadelphia, PA 7/1/00-6/30/04 Associate Professor of Pathology and Laboratory Medicine University of Pennsylvania School of Medicine, Philadelphia, PA 7/1/04-6/30/05 Professor of Pathology and Laboratory Medicine University of Pennsylvania School of Medicine, Philadelphia, PA

2

7/1/05-present Carl V. Weller Professor and Chair of Pathology University of Michigan Medical School, Ann Arbor, MI

1/1/2012-present Professor of Internal Medicine University of Michigan Medical School, Ann Arbor, MI CLINICAL/HOSPITAL APPOINTMENTS 7/1/93-6/30/99 Assistant Attending Pathologist, Division of Surgical Pathology, Barnes-Jewish Hospital, BJC

Healthcare Network, St. Louis, MO 7/1/93-6/30/99 Co-Director, Hematopathology Training Program, Washington University School of Medicine, St. Louis, MO 7/1/99-6/30/05 Director of Hematopathology, Department of Pathology and Laboratory Medicine, University of Pennsylvania Health System 7/1/03-6/30/05 Co-Director of Hematologic Malignancies Program, Abramson Cancer Center 7/1/05-present Director of Clinical Laboratories, University of Michigan Health System 7/1/05-present Director, Division of Sponsored Research, Department of Pathology

9/15/10-present Director of Personalized Medicine Strategy Deployment Team, Office of Executive Vice President for Medical Affairs, University of Michigan Health System RESEARCH INTERESTS Epigenetic regulation of transcription and its disruption in disease Development of mechanism-based therapies for acute leukemia Applications of next generation sequencing to clinical diagnostics and personalized medicine SCIENTIFIC ACTIVITIES 1996-present Editorial Board, American Journal of Clinical Pathology 1999-present Reviewer for PNAS, Blood, Cell, Cancer Investigation, Leukemia, EMBO Journal, Cancer Cell,

Cancer Research, Developmental Cell, Molecular Cell, Genes Chromosomes and Cancer, Modern Pathology, Human Pathology, American Journal of Clinical Pathology, Experimental Hematology, Clinical Cancer Research, DNA and Cell Biology, Oncogene, Gene, Molecular and Cellular Biology, Nature Cell Biology, Nature, Nature Medicine, Nature Reviews Cancer, Nature Structural and Molecular Biology, Nucleic Acids Research, Pediatric Blood and Cancer, Science Translational Medicine, Translational Research, Leukemia Research, PLos One

2007-present Founding Editorial Board Member, International Journal of Clinical and Experimental Pathology. 2007-present Founding Editorial Board Member, Clinical and Translational Science 2007-2010 Editorial Board Member, Experimental Hematology 2011-present Founding Editorial Board Member, American Journal of Blood 2013-present Editorial Board Member, Pathology Discovery GRANT SUPPORT Current: R01 CA151425-01 (P.I.-Hess) 8/1/11-7/31/16 20% effort NIH/NCI $226,490 annual direct costs

3

New Therapeutic Targets in Acute Leukemia R01 CA160467-01 (P.I.-Grembecka) 9/1/11-07/31/16 NIH (Hess co-Investigator) $207,501 annual direct costs 5% effort Development of Novel anti-Leukemia Agents Targeting the Menin-MLL Interaction Leukemia and Lymphoma Society of America 10/1/07-9/30/17 10% effort SCOR (P.I.-Licht) Project 1 (P.I.-Hess) $180,000 annual direct costs Consortium for the Study of Chromatin Biology and Epigenetic Targeting in Hematologic Malignancies Leukemia and Lymphoma Society of America 10/1/11 – 9/30/14 5% effort Translational Research Program (P.I.-Grembecka) $180,018 annual direct costs Aim 1: In vivo efficacy studies of menin-MLL inhibitors in Mice Model of MLL-AF9 leukemias (P.I.-Hess) $37,541 annual direct costs K99 CA158136-01 (Sponsor-Hess, P.I.-Muntean) 7/15/11-6/30/13 0% effort NIH/NCI $99,708 annual direct costs (mentor) Post-Translational Regulation of MLL in Leukemogenesis ASH Scholar Award (career development award for Dr. Andrew Muntean) 7/15/2011-6/30/13 0% effort American Society of Hematology $100,000 annual direct costs (mentor) 1F30 HL095280-01 (Training grant for Cailin Collins) 7/01/12-6/30/17 0% effort NHLBI/NIH $39,125 annual direct costs (mentor) The Role of Collaborator Proteins in Hoxa9-mediated Leukemogenesis Past: Co-P.I. (with Dr. Stanley Korsmeyer) 7/1/94-7/1/96 50% effort Parker Hughes Foundation $95,652 annual direct costs Mechanisms of Leukemogenesis & Chemotherapeutic Resistance in Acute Lymphoblastic Leukemia P.I.-Hess 3/13/00-11/30/00 0% effort University of Pennsylvania Cancer Center $25,000 Deregulation of MYC Signaling by MLL Fusion Proteins KO8 HL71204-01 (P.I.-Martin) 7/15/02-6/30/05 0% effort NIH $100,000 annual direct costs (mentor) Mechanisms of Transformation by MLL Fusion Proteins Leukemia and Lymphoma Society of America 7/1/2001-6/30/2006 10% effort SCOR (P.I.-June) Project #8 (P.I.-Hess) $108,500 annual direct costs The SWI/SNF complex as a therapeutic target in acute leukemia 5P30CA016520-30 (P.I. – Glick ) UPENN Comprehensive Cancer Center 12/1/04-11/30/09 10% effort NIH Core Grant $4,777,869 total annual direct costs Co-Director of Hematologic Malignancies Program

4

R01 CA78815-07 (P.I.-Hess) 7/1/98 – 6/30/2008 20% effort NIH $211,500 annual direct costs Mechanisms of Hox gene regulation by MLL MICHR Grant 7/1/07-6/30/08 0% effort Project 1 (P.I.-Hess) $55,000 direct costs New approaches to improve bone marrow transplantation in leukemia Gregory Margolies Fund for Center for Chemical Genomics 10/1/07-9/30/08 10% effort Small molecule inhibition of oncogenic fusion $20,000 direct costs (support for CCG screening) proteins in acute leukemia. University of Michigan Computational Medicine and Biology (CCMB) Pilot Research Grant (P.I. – Hess) University of Michigan 1/9/09 – 12/31/09 0% effort $50,000 direct costs R01 CA116570-01A1 (P.I.-Hess) 9/15/06-7/31/11 20% effort NIH $172,353 annual direct costs Mechanisms of Hox Protein-Mediated Transformation 1F30 HL095280-01 (Training grant for Stephanie Jo) 2/01/09-1/31/12 0% effort NHLBI/NIH $31,558 annual direct costs (mentor) The Role of the MLL Partner Associated Complex (MPAC) in Leukemia R01 CA92251-01 (P.I.-Hess) 9/27/07-8/31/12 20% effort NIH/NCI $177,293 annual direct costs Transcriptional Deregulation by MLL Fusion Proteins Leukemia and Lymphoma Society (P.I.-Grembecka) 10/1/11-9/30/12 2.5% effort (Hess co-Investigator) $33,821 annual direct costs In vivo Efficacy Studies of Menin-MLL Inhibitors in Mice Model of MLL-AF9 Leukemia Pending: RO1 (P.I. Hess) 9/1/12-8/30/17 15% effort NIH $250,000 annual direct costs Role of Collaborator proteins in HOXA9-Mediated Leukemogenesis ACS Research Scholar Grant (P.I. Grembecka) 07/01/2011 – 06/30/2015 2.5% effort (Hess co-Investigator) $200,000 annual direct costs Targeting LEDGF interactions to inhibit MLL fusion proteins in leukemia CERTIFICATION AND LICENSURE Specialty Certification: 1993 American Board of Pathology (Anatomic Pathology) 1995 American Board of Pathology (Hematology)

5

Licensure: Missouri (7/1/93-1/31/00) MD102862 Pennsylvania (7/1//99-7/1/05) MD 068415L Michigan (7/1/05 – present) MD 4301086490 EXECUTIVE EDUCATION 1/18/06-1/28/06 Program for Chiefs of Clinical Services, Harvard School of Public Health, Boston, MA 6/25/07-6/27/07 Program on Negotiation for Senior Executives, Harvard Law School, Boston, MA 2/11/08–4/15/08 Leadership Development Program, University of Michigan Healthcare Leadership Institute, Ann Arbor, MI 4/15/08–4/18/08 Forces of Change: New Strategies for the Evolving Health Care Market, Harvard School of Public Health, Boston, MA 2/9/10-2/10/10 Faculty Group Practice Lean Leadership Program, University of Michigan Medical School 9/7/11-10/10/12 HMP 630 The Business of Biology, University of Michigan 12/1/11-12/2/11 Linkage Leadership Academy, University of Michigan 3/3/13- 5/13/13 Leadership Strategies for Information Technology in Healthcare, Harvard School of Public Health, Boston, MA HONORS AND AWARDS 1976-1977 Yale University Frontiers in Applied Science Program 1977-1978 Columbia University Science Honors Program 1978 National Merit Scholarship Finalist 1978 Dr. Harris Scholarship 1978 English Department Award, Roger Ludlowe High School 1979 Summer Research Fellowship. Institute of Cancer Research, Columbia University College of Physicians and Surgeons 1980-1982 Howard Hughes Medical Institute Research Fellowship, The Johns Hopkins University 1982 Phi Beta Kappa 1982 General and Departmental Honors, The Johns Hopkins University 1982-1989 Medical Scientist Training Program 1989 Alpha Omega Alpha Honor Medical Society 1999 John Morgan Society 2003 Morton F. Mason Lectureship, University of Texas Southwestern 2004 American Society for Clinical Investigation 2007 Madison Who’s Who Among Executives and Professionals 2008 Madison Who’s Who Among Executives and Professionals Honors Edition 2008 Strathmore’s Who’s Who Worldwide 2008 Cambridge Who’s Who Among Executives and Professionals, Healthcare Honors Edition 2009 Ramzi S. Cotran Lectureship, New England Society of Pathologists 2011 Gregory Derringer Pathology Grand Rounds, Indiana University School of Medicine 2011 University of Michigan Health System Making a Difference Award 2012 University of Michigan Health System Making a Difference Award MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES National Societies:

6

1992-present Fellow, College of American Pathologists 1993-present American Society of Hematopathologists 1994-present United States and Canadian Academy of Pathology 1994-present American Society of Investigative Pathology 2009-present ASIP Meritorious Awards Committee Member 1997-present American Society of Hematology 2004-present American Society of Investigative Pathology 2000-present American Association for Cancer Research 2005-present Association of Pathology Chairs 2005-present Association of Pathology Chairs Research Committee 2006-present Pluto Society 2006-present American College of Physician Executives 2007-present International Society of Experimental Hematology 2009-present American Society of Investigative Pathology Meritorious Awards Committee 2012-present Association for Molecular Pathology

Local Societies: 1999-present Full member, University of Pennsylvania Cancer Center 2000-2005 Member, Cell and Molecular Biology Graduate Group, University of Pennsylvania School of Medicine 2005-present Member, Cell and Molecular Biology Graduate Group, University of Michigan Medical School 2005-present Member, University of Michigan Cancer Center 2005-present Member, Program in Biomedical Sciences, University of Michigan Medical School 2006-present Member, Michigan Society of Pathologists 2005-present Member, A. James French Society COMMITTEE AND ADMINISTRATIVE SERVICE National and International: 1996-1999 Cancer and Lymphoma Study Group B (CALGB) Pathology Committee 2001-2005 NIH Cancer and Molecular Pathobiology Study Section, charter member 2002 NIH Follicular Lymphoma Vaccine Trial, Co-investigator 2003 NIH Molecular Genetics of MLL-Associated Leukemia PO1 Site Visit, member,

Loyola University 2003 American Society of Hematology Abstract Review Committee 2003 NIH Molecular Mechanisms of Multiple Myeloma P01 Site Visit, Mayo Clinic 2003-2005 Council of Healthcare Advisors 2006 American Association for Cancer Research (AACR) Program Committee 2006 American Society of Hematology Abstract Review Committee 2006 Ad Hoc reviewer, NIH Cancer and Molecular Pathobiology Study Section 2007 Coordinating reviewer, American Society of Hematology, Abstract Review Committee 2007-present Association of Pathology Chairs Research Committee 2007 Grant reviewer, National Cancer Institute of Canada 2007 Ad Hoc reviewer, NIH Molecular Oncogenesis Study Section 2008 Co-Organizer, MLL Summit Workshop, Stowers Institute, Kansas City, MO 2008 Ad Hoc reviewer, NIH Biological Chemistry and Macromolecular Biophysics Study Section 2008-10 Grant reviewer, Leukemia Research Fund, University of Minnesota Cancer Center 2008 Chair, NIH Cancer Genetics and Profiling Special Emphasis Panel 2008 Grant Reviewer, Wellcome Trust

7

2008 American Society of Hematology Career-Development Lunch Leader 2009 Chair, NIH Basic and Translational (OBT) IRG 2009 Grant reviewer, NIH Challenge Grants in Health and Science Research 2009-10 Grant reviewer, National Medical Research Council, Singapore 2010 Ad Hoc Promotions Committee, Harvard Medical School 2010 Scientific poster reviewer, American Society for Clinical Investigation 2010 Ad Hoc reviewer, NIH Basic and Translational (PBT) Special Emphasis Panel 2010 Ad Hoc reviewer, NIH Endocrinology, Metabolism, Nutrition, and Reproductive Sciences (EMNR) Special Emphasis Panel 2010 Chair, NIH Basic and Translational (OBT) IRG 2010 External Advisor, Chromatin and Chromosome Dynamics Search, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération (LBCMCP), Toulouse, France. 2010 American Society of Hematology Abstract Review Committee 2011 Chair, NIH Basic and Translational (OBT) IRG 2011 Grant reviewer, Cancer Research UK, United Kingdom 2011 Lymphoid Malignancy Session Chair, 2011 FASEB Hematologic Malignances Research Conference, Saxtons River, VT 2011 Grant reviewer, Kay Kendell Leukaemia Fund, United Kingdom 2011 American Society of Hematology 2011 Annual Meeting Session Moderator, San Diego, CA 2012 American Society of Hematology Career-Development Lunch Leader 2012 Grant reviewer, U.S.-Israel Binational Science Foundation 2012 Grant reviewer, Lymphoma and Leukemia Foundation, United Kingdom 2012 Discussion Leader and Reviewer, NIH Research Program Branch, Special Emphasis Panel 2012-present Leukemia and Lymphoma Society SCOR Grant Review Committee 2013 Cancer Research UK Programme Review, London, United Kingdom (pending) 2013 Reviewer, NIH Metabolism Branch, NCI (pending) University: 2000-2002 Senate Executive Committee, University of Pennsylvania 2009 Drug Discovery Institute Committee, University of Michigan 2009 Biointerface Committee, University of Michigan 2010 Office of Vice President for Research, Grants and Awards Reviewer 2010-present Director UMHS Personalized Medicine Strategy Deployment Team 2011 Chair, Office of the Provost, University Advisory Committee on Life Sciences Institute 2011 UMHS CFO Search Committee 2011 Advisor to UMHS CIO search 2011-present Chair, North Campus Research Complex Financial Advisory Committee 2011-present North Campus Research Complex Portfolio Advisory Committee 2012-present Drug Discovery Institute Steering Committee 2012-present Advisory Board Member, Michigan Regional Comprehensive Metabolomics Resource Core 2012-present Advisory Board Member, Department of Health Management and Policy, School of Public Health 2012-present Cofounder and Chairman of Board of Paradigm, a sequencing-based diagnostics company Medical School: 1999-2005 M.D., Ph.D. Admissions Committee, University of Pennsylvania School of Medicine 2000-2001 Academic Review Committee, Department of Dermatology 2001-2005 Stem Cell Core Advisory Committee 2001 Co-Chair, University of Pennsylvania Cancer Center Symposium Leukemia and Myelodysplasia: Advances in Biology, Diagnosis, and Management

8

2001 Chair, Cytogenetics Planning Committee, University of Pennsylvania 2005-present University of Michigan Comprehensive Cancer Center Executive Committee Member 2005-present VA Dean’s Advisory Committee Member 2005-2008 Endowment for the Basic Sciences Initiative in Protein Chemistry, Member 2005-2009 Senior Leadership Council Member 2005-present Dean’s Advisory Committee Member 2005-present Medical Scientist Training Program Policy Committee 2005-present Biomedical Sciences Scholars Program Selection Committee 2005-present Molecular and Cellular Pathology Graduate Program Oversight Committee 2006-present Medical Scientist Training Program Policy Committee 2006-present Michigan Center for Translational Pathology Executive Committee 2006-present Faculty Group Practice Board – Voting Member 2006-2007 Faculty Group Practice Board Finance Subcommittee 2006-2008 Medical School Executive Committee 2006-2008 Medical School Executive Committee Business Subcommittee 2007-present Medical School Compensation Committee 2007-present Dean’s Standing Search Committee for Department Chairs 2007-present Faculty Group Practice Budget and Finance Executive Committee 2008-2009 Chair, Department of Internal Medicine Chair Search Committee 2008 Chair, Pfizer Advisory Finance Committee 2008-2009 Faculty Group Practice Hospital Transfers Committee 2010 GI SPORE Advisory Committee 2009-2010 Chair, Medical School Business Planning and Financial Funds Flow Task Group 2010-present Leukemia Director Search Committee, Department of Internal Medicine 2010-present Liaison Committee on Medical Education (LCME) Self Study Task Force 2011-present Faculty Administrative Service Agreement (FASA) Task Force 2011-present Executive Compensation Committee 2012-present Faculty Salary Committee 2012-present Research Board of Directors 2012-present Executive Committee of Research Board of Directors 2012-present Co-Director, Personalized Medicine FastForward Initiative 2012-present Translational Research/Ambulatory Care Cancer Center Administrative Lead Team Department: 1999- Department of Pathology and Laboratory Medicine Transfusion Medicine Search

Committee 2000-2001 Department of Pathology and Laboratory Medicine Clinical Chemistry Search Committee 2003 Chair, Department of Pathology and Laboratory Medicine, Hematopathology/Surgical

Pathology Search Committee 2003 Department of Pathology and Laboratory Medicine Surgical Pathology Search Committee 2002 Department of Pathology and Laboratory Medicine Clinical Chemistry Search Committee 2005 Chair, Director of Anatomic Pathology Search Committee 2005 Chair, Director of Clinical Informatics Search Committee 2005-present Director, Division of Sponsored Research, Department of Pathology 2005-2006 Acting Director, Division of Translational Pathology, Department of Pathology 2006 Chair, Director of Finance and Administration Search Committee, Department of Pathology 2006-2007 Chair, Lean Implementation Steering Committee 2007-present Chair, Marketing Oversight Committee 2008-present Chair, MLabs Executive Committee

9

TEACHING ACTIVITIES 1993-1999 Co-Director Hematopathology Fellowship, Washington University School of Medicine 1993-1999 M2 Medical Student Pathology Lab Director, Washington University School of Medicine 1999-2005 Director, Hematopathology Fellowship, University of Pennsylvania Health System 1999-2005 Course Director, Hematopathology/Hematology Section, Module II, Curriculum 2000

for first-year medical students, University of Pennsylvania School of Medicine 1999-present Lectures to Anatomic Pathology and Laboratory Medicine Residents (acute leukemia,

lymphoma classification, laboratory management, general management, negotiation) 2000-2005 M.D., Ph.D. Mentoring Committee 2000-2005 NIH K08 Mentoring Committee, Dr. Bruce Hug 2000-2005 NIH K08 Mentoring Committee, Dr. Lynn Wang 2000-2002 Faculty Mentor, Dr. Elizabeth Genega 2000-2003 Faculty Mentor, Dr. Plamen Kossev 2001-2003 Faculty Mentor, Dr. John Choi 2002-2005 NIH K08 Mentor and Advisor, Dr. Mary Ellen Martin 2003-2005 Cell Growth and Cancer Curriculum Committee 2003-2005 Ph.D. Thesis Committee, Penny Gilbert 2004-2005 Ph.D. Thesis Committee, Yun Li 2005 Ph.D. Thesis Committee, Amy Kondyra 2006 Preliminary Examination Committee, CMB, Ferdous Barlaskar 2007 Chair, Preliminary Examination Committee, Victoria Cancelli 2007-2009 NIH K08 Mentor and Chair of Mentoring Committee, Dr. Kajal Sitwala 2008 Ph.D. Preliminary Committee, Heather Ames 2008 Ph.D. Preliminary Committee, Stephanie Jo 2009-2011 Ph.D. Thesis Committee, Yongsheng Huang 2009 Ph.D. Preliminary Committee, Tan Jiaying 2009 Ph.D. Preliminary Committee, Chenxi Shen 2010 Ph.D. Preliminary Committee, Jingya Wang 2010 Ph.D. Preliminary Committee, Cailin Collins 2011 NIH K99 Mentor, Dr. Andrew Muntean 2011 American Society of Hematology Scholar Award, Mentor, Dr. Andrew Muntean 2011-present Lecturer, The Business of Biology, HMP 630, Ross School of Business 2012-present Ph.D. Thesis Committee, Garrett Gibbons 2012-present Lecturer, Cancer Biology 553, University of Michigan Medical School LABORATORY TRAINEES Trainee Name Training Years of

Support Prior Degrees/Institution

Research Topic Current Position

Galoian, Karine

Postdoc 2001- Ph.D., Armenian Academy of Sciences

Mechanisms of Transformation by MLL

Research Assistant Professor, University of Miami

Milne, Thomas Predoc 2001 - 2004

M.S., University of British Columbia, 2004

Mechanisms of Hox gene regulation by MLL

Assistant Professor Oxford University, U.K.

Monroe, Sara Predoc 2005 -2010

BS, Florida State University Tallahassee 2000

Role of Wildtype MLL in Transformation

Ph.D. Family leave

Martin, Mary Ellen

Postdoc 2002-2005

M.D. SUNY Health Sciences Center 1996 B.S. Cornell University 1976

Dimerization dependent transformation by MLL fusion proteinsMLL regulation

Assistant Professor, Fox Chase Cancer Center

10

Yang, Zhaohai Postdoc 2004-2005

M.D., Beijing Medical University 1993 Ph.D., University of Pennsylvania, 2001

Role of MLL protein in cell cycle arrest and monocytic differentiation

Assistant Professor, Pennsylvania State College of Medicine

Yu, Zaifang Postdoc 2004-2005

M.D., Beijing Medical University 1991

Transcriptional targets of Hoxa9

Research Associate, Univ of Pennsylvania School of Medicine

Caslini, Corrado Postdoc 2005-2009

Ph.D, University of Milan 1996

Role of the MLL amino terminus in transformation

Assistant Professor, University of Michigan

El-Osta, Mohamad

Postdoc 2005-2007

Ph.D., Oklahoma State University 2005

Proteomics of MLL associated leukemia

Research Associate, University of Georgia

Sitwala, Kajal Postdoc 2005-2009

MD, PhD, University of Michigan 2004

Mechanisms of Transformation by HoxA9

Attending Pathologist Marshfield Clinic, Marshfield, WI

Jiaying, Tan Predoc 2007 B.S. Wuhan University,China 2005

Mechanisms of MPAC activity

Ph.D. Postdoctoral fellow Novartis, China

Crawford, Brendan

Predoc 2006-2007

B.S. University of Notre Dame 2004

Molecular mechanism of menin in MLL-mediated leukemogenesis

M.D. Ph.D. Resident in Pediatrics University of Michigan

Udager, Aaron Predoc 2005 A. B. Harvard, 2003 Role of PHD fingers in MLL regulation

M.D. Ph.D. Resident in Pathology University of Michigan

Muntean, Andrew Postdoc 2006- Ph.D., University of Chicago 2006

Function of PHD fingers of Mll in leukemogenesis

Assistant Professor University of Michigan

Dandekar, Monisha

Postdoc 2007-2008

M.D., UT Southwestern Medical Center, Dallas, 2006

Genome-wide binding patterns for HoxA9 and Meis1

Dermatopathology Fellow, University of Michigan

Jo, Stephanie Predoc 2007- B.A., Northwestern University

Function of MPAC proteins

MD. Ph.D. student, University of Michigan

Sanders, Daniel Undergrad 2007-2009

B.A. University of Michigan 2009

Regulation of Hox genes in the PI3 Kinase Pathway

D.O. student, Michigan State University

Connelly, James Postdoc 2007-2009

M.D., Washington University, 2003

The effect of the MLL gene and telomere maintenance

Lecturer, Department of Pediatrics, University of Michigan

Huang, Yongsheng

Predoc 2009- M.S. Michigan Technological University 2002

Genome-wide assessment of HOX and MEIS1 binding sites

Ph.D. (Bioinformatics) Senior Research Scientist, Merck Inc.

Wang, Jingya Predoc 2009- B.S. Fudan University, China 2008

Role of ubiquitination in transcriptional regulation by MLL

Ph.D. student

Nagaraja, Surya Undergrad 2009- Role of HOXA9 and MEIS1 in transformation

Undergrad, University of Michigan, Ann Arbor

Grenowicz, Eric Undergrad 2009- 2011

B.A. University of Michigan

Role of DOT1L in normal and leukemic hematopoiesis

M.D. student, Wayne State University

11

HEMATOPATHOLOGY FELLOWS (while Fellowship Director) Year Name Location Current Position 1993-94 Richard Clatch, M.D., Ph.D. Washington University, St. Louis Consolidated Medical Laboratories, Lake

Forest, IL 1995-96 Tom Jelic, M.D., Ph.D. Washington University, St. Louis Charlestown Area Medical Center, West

Virginia 1995-96 Alden Chesney, M.D. Washington University, St. Louis Staff Hematopathologist, Sunnybrook Health

Sciences Centre, University of Toronto 1996-97 Zahid Kaleem, M.D. Washington University, St. Louis Chief of Pathology, Missouri Baptist Hospital,

St. Louis, MO 1997-98 Carolyn Hathaway, M.D. Washington University, St. Louis Private Practice, Tempe, Arizona 1998-99 Richard Burack, M.D., Ph.D. Washington University, St. Louis Associate Professor and Director of

Hematopathology,University of Rochester, Rochester, NY

1999-00 Kerri Santiago, M.D. University of Pennsylvania University Medical Center, Louisiana State University, Lafayette, LA

2000-01 Jianguo Tao, M.D., Ph.D. University of Pennsylvania Associate Professor, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

2000-01 Michele E. Paessler, D.O. University of Pennsylvania Assistant Professor of Hematology and Flow Cytometry, Children's Hospital of Pennsylvania

2001-03 Jo-Anne Vergilio, M.D. University of Pennsylvania Assistant Professor of Pathology, Harvard Medical School; Director of Hematopathology, Boston Children's Hospital, Boston, MA

2002-03 Friederike Kreisel, M.D. University of Pennsylvania Associate Professor of Pathology and Immunology, Washington University School of Medicine St. Louis

2003-04 Arpad Szallasi, M.D., Ph.D. University of Pennsylvania Hematopathologist and Medical Director for Transfusion Services, Monmouth Medical Center, Long Branch, NJ

Collins, Cailin Chase, Jennifer Nawer, Humaira Sun, Yuqing Wu, Laura Ma, Peilin Morgan, Mary

Predoc Predoc Undergrad Predoc Undergrad Postdoc Predoc

2010- 2011 2011- 2012- 2012- 2012- 2013

B.A. Williams College 2008 B.S. South Dakota State 2011 B.S. Peking University 2006 Cornell University M.D. Ph.D. Harbin Medical University, China 1997, 2004 B.S. University of California, San Diego

Mechanisms of transformation by HOXA9 and MEIS1 Role of HOXA9 and MEIS1 interacting proteins Regulation of FLT3 transcription by HOXA9 HOXA9 binding sites In lymphoid cells Regulation of MLL by ubiquitination Signal transduction pathways converging on HOXA9 regulated enhancers Postranslational regulation of DOT1l

M.D., Ph.D. student Rotating Ph.D. student Undergrad, University of Michigan, Ann Arbor Ph.D. student Undergrad, Cornell University Postdoc Ph.D. student

12

2003-04 Xianfeng Frank Zhao, M.D., Ph.D. M.B.A.

University of Pennsylvania Associate Professor of Pathology and Director of Hematopathology, University of Maryland School of Medicine

2004-05 Sindhu Cherian, M.D. University of Pennsylvania Assistant Professor of Laboratory Medicine, Associate Director of the Hematopathology Laboratory, University of Washington, Seattle, WA

2004-05 Huan-You Wang, M.D., Ph.D. University of Pennsylvania Associate Professor of Pathology and Co-Director of Hematopathology, University of California, San Diego

EXTRAMURAL INVITED PRESENTATIONS “The Role of the Mixed Lineage Leukemia Gene (MLL) in Hox Gene Regulation and Hematopoiesis” Department of Pathology, Northwestern University, February 6, 1997. "Mechanisms of Hox Gene Regulation by MLL," St. Jude Children’s Research Hospital, Memphis, Tennessee, February 6, 1998. "Mechanisms of Hox Gene Regulation by MLL," Department of Biochemistry, St. Louis University School of Medicine, St. Louis, Missouri, October 7, 1998. "Mechanisms of Hox Gene Regulation by MLL," British Columbia Cancer Agency, Vancouver, British Columbia, Canada, January 11, 1999. "Mechanisms of Hox Gene Regulation by MLL," Forbeck Symposium on Infant Leukemia, Owatonna, Minnesota, June 16, 1999. "The role of the mixed lineage leukemia protein (MLL) in Hox gene regulation and hematopoiesis", University of Minnesota Cancer Center, Minneapolis, Minnesota, October 12, 1999. "The role of the mixed lineage leukemia protein (MLL) in Hox gene regulation and hematopoiesis", Kimmel Cancer Institute, Thomas Jefferson University School of Medicine, Philadelphia, Pennsylvania, February 17, 2000. "Mechanism of Hox gene regulation by the mixed lineage leukemia protein", University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, March 8, 2000. "Transcriptional Regulation by the Mixed Lineage Leukemia Protein", Aichi Cancer Institute, Nagoya, Japan, October 18, 2000. "Neoplasia in East and West: Nodal Lymphomas", (Arthur Purdy Stout Society of Surgical Pathologists Companion Meeting, XXIII International Congress of the International Academy of Pathology,) Nagoya, Japan, October 19, 2000. "Transcriptional Regulation by the Mixed Lineage Leukemia Protein", (Research Institute for Microbial Diseases) Osaka University, Osaka, Japan, October 20, 2000. "Transcriptional Deregulation by MLL Fusion Proteins", Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, September 20, 2001.

13

"MLL controls histone acetylation and H3 lysine 4 methylation at the Hoxc8 locus", 12th IMP Spring Conference, Vienna, Austria, May 25, 2002. “MLL: Editor of the Histone Code in Development and Leukemia" Boston University School of Medicine, Boston, MA, December 6, 2002. "Mechanisms of Hox Gene Regulation by MLL," Department of Zoology, University of British Columbia, Vancouver, British Columbia, Canada, February 24, 2003. "MLL: Epigenetic Regulator of Hox Gene Expression in Development and Leukemia" University of Utah Health Sciences Center, Salt Lake City, UT, March 21, 2003. "MLL: Editor of the Histone Code in Development and Leukemia" Morton F. Mason Lectureship, Department of Pathology, University of Texas Southwestern, Dallas, TX, May 6, 2003. "Regulation of Histone Methylation in Development and Leukemia” NIH Cancer and Molecular Pathobiology/Metabolic Pathology Workshop, San Diego, CA, June 5, 2003. "MLL: Regulator of the Histone Code in Development and Leukemia" Children’s Cancer Research Institute, University of Texas at San Antonio, San Antonio, TX, August 28, 2003. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays" American Society of Hematopathology Workshop on Pediatric Hematopathology, St. Jude Children’s Research Hospital, Memphis, TN, October 23, 2003. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " Loyola University of Chicago, Oak Bend, IL, November 18, 2003. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " Department of Biochemistry, St. Louis University School of Medicine, St. Louis, MO, December 1, 2003. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " Washington University School of Medicine, St. Louis, MO, December 2, 2003. "MLL: Editor of the Histone Code in Development and Leukemia" Department of Microbiology and Immunology, East Carolina State University, Greenville, NC, December 16, 2003. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " Department of Pathology, Yale University School of Medicine, New Haven, CT, February 17, 2004. "Transcriptional Regulation of Hox Genes" NIH Workshop on Homeobox Genes and Adult Tissue Remodeling: Focus on Mammary Gland, Bethesda MD, March 8, 2004. “MLL: Editor of the Histone Code in Development and Leukemia" University of Chicago Cancer Center, Chicago, IL, April 21, 2004. “Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays" Robert Wood Johnson School of Medicine, Piscataway, NJ, May 7, 2004.

14

“Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays”, University of Michigan Medical School, Ann Arbor, MI, July 13, 2004. “Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays" Mt. Sinai Medical Center, New York, NY, October 8, 2004. "Frontiers in Hematopathology" (plenary speaker) 26th Congress of Hematology, Cairo, Egypt, December 15, 2004. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays ", Lineberger Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, February 15, 2005. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays ", Division of Medical Oncology, University of Colorado Cancer Center, Denver, CO, February 22, 2005. "Disordered Chromatin Regulation in Cancer and its Implications for Cancer Diagnosis and Therapy" Long Course in Advanced Molecular Pathology, United States and Canadian Academy of Pathology 2005 Annual Meeting, San Antonio, TX, March 4, 2005. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays ", American Society for Investigative Pathology 2005 Annual Meeting, San Diego, CA, April 5, 2005. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays" 2005 FASEB Summer Conference on Hematological Malignancies, Saxtons River, VT, July 30, 2005. “New Paradigms for Pathology Department Organization: A Beginner’s View” Association of Pathology Chairs, Western and Midwestern Division, Kauai, Hawaii, November, 2005. “Transformation by MLL”, Second Bi-Annual ICH/GOSH Paediatric Haematology-Oncology Symposium: Molecular Basis of Childhood Leukemia, London, England, March 23, 2006. “Building Research Infrastructure” Association of Pathology Chairs Annual Meeting, Colorado Springs, CO, July 14, 2006. “Training Academic Pathologists” Association of Pathology Chairs Western and Midwestern Division, San Diego, CA, October 27, 2006. “Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice and Microarrays” Johns Hopkins University School of Medicine Workshop on Clinical Targeting of Epigenetic Changes in Cancer, Phoenix, AZ, January 12, 2007. “Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice and Microarrays” NIH Transcription Factors Interests Group, Bethesda, MD, February 1, 2007.

“Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice and Microarrays” Massachusetts General Hospital Cancer Center, Boston, MA, April 4, 2007. “What Hematopathology Tells Us About the Future of Pathology Informatics”, World Congress on Pathology Informatics (plenary speaker), Brisbane, Australia, August 16, 2007. “Transcriptional Deregulation by MLL Fusion Proteins”, University of Kansas Medical Center, Kansas City, KS, September 6, 2007.

15

“Epigenetic Dysregulation in Mixed Lineage Leukemia”, International Society for Experimental Hematology (plenary speaker), Hamburg, Germany, September 28, 2007. “Quantitative cost-benefit analysis on co-locating research labs with clinical facilities”, Academic Medical Centers 2007, Tradeline, San Diego, CA, December 3-4, 2007. “Overview of Transcription Factor Targets in Leukemia”, American Society of Hematology Annual Meeting, Atlanta, GA, December 8-9, 2007. “MLL: A Histone Methyltransferase Disrupted in Acute Leukemia”, Pluto Society Annual Meeting, Cabo San Lucas, Mexico, March 8, 2008. “Epigenetic Dysregulation in Mixed Lineage Leukemia”, American Society for Investigative Pathology 2008 Annual Meeting, San Diego, CA, April 8, 2008. “Mechanisms of Transformation by MLL Fusion Proteins, Third Bi-Annual ICH/GOSH Pediatric Haemotology-Oncology Symposium: Molecular Basis of Childhood Leukaemia, London, England, May 1, 2008. “Mechanisms of Transformation by MLL Fusion Proteins”, Conference Co-Organizer and Chair Session III, Stowers Institute for Medical Research, Kansas City, MO, September 6, 2008. “Epigenetic Dysregulation in Acute Leukemia”, Association for Molecular Pathology 2008 Annual Meeting, plenary speaker, Grapevine, TX, October 31, 2008. “Team Science: The Pathologist as Driver”, Association of Pathology Chairs Annual Meeting, Colorado Springs, CO, July 18, 2008. “Strategies for Determining Academic Salaries and Incentives”. Association of Pathology Chairs Western and Midwestern Division, Maui, Hawaii, November 14, 2008. “Ídentification of New Therapeutic Targets in Acute Leukemia” Department of Pathology, University of Pittsburgh Medical Center, February 11, 2009. “Epigenetic Dysregulation in Acute Leukemia”, Molecular Mechanisms of Normal and Malignant Hematopoiesis, Sonderforschungsbereich 684, Munich, Germany, April 23, 2009. “Mechanisms of Hox Gene Deregulation in Acute Leukemia”, Department of Pathology Joint Grand Rounds, Harvard Medical School, Boston, MA, May 4, 2009. “AML Diagnosis in the 21st Century”, Ramzi Cotran Lectureship, New England Society of Pathologists, Boston, MA, May 5, 2009. “Mechanisms of Epigenetic Dysregulation in Acute Leukemia”, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, May 7, 2009. “Mechanisms of Epigenetic Dysregulation in Acute Leukemia”, Department of Pathology, University of Chicago, Chicago, IL, May 8, 2009. “Pathology Outreach Programs”, Workshop Chair, Association of Pathology Chairs 2009 Annual Meeting, Seattle, WA, July 15, 2009.

16

“Mechanisms of Transformation by MLL Fusion Proteins”, 2009 FASEB Summer Research Conference on Hematologic Malignancies, Saxtons River, VT, August 23, 2009. “AML Diagnosis in the 21st Century”, Clarient Continuum, Dearborn, MI, September 12, 2009. “Epigenetic Dysregulation in Acute Leukemia”, American Society of Nephrology 42nd Annual Meeting, San Diego, CA, October 28, 2009. “Mechanisms of HOX Gene Deregulation in Acute Leukemia”, The University of Alabama at Birmingham, Division of Molecular & Cellular Pathology, December 10, 2009. “Interviewing for Your First Faculty Position”, United States and Canadian Academy of Pathology 99th Annual Meeting, March 21, 2010. “Mechanisms of HOX Gene Deregulation in Acute Leukemia” University of California, San Diego, Department of Pathology, May 24, 2010. “HOX proteins regulate transcription through evolutionarily conserved enhancer elements” American Society of Hematology Myeloid Workshop, Orange County, FL, December 3, 2010. “Targeting Mechanisms of MLL Recruitment” 5th Biennial Workshop on Clinical Translation of Epigenetics in Cancer Therapy” San Diego, CA, January 15, 2011. “Mechanisms of Transformation by HOX Proteins”, 2011 FASEB Summer Research Conference on Hematologic Malignancies, Saxtons River, VT, August 3, 2011. “Interviewing for Your First Job”, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, October 13, 2011. “A Path Toward New Therapies for Acute Leukemia”, Gregory Derringer Pathology Grand Rounds, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, October 13, 2011. “Mechanisms of Transcriptional Regulation and Transformation by HOXA9”, 9th International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, University of Cincinnati, Cincinnati, OH, May 6-9, 2012. “Mechanisms of Transcriptional Regulation and Transformation by HOXA9”, Scientific Committee on Myeloid Biology, 2012 American Society of Hematology Annual Meeting, Atlanta, GA, December 8-12, 2012. “The Role of the MLL-PAFc Axis in Hematopoiesis and Leukemia”, 6th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy, Ashville, NC, January 18-21, 2013. “Mechanisms of Transcriptional Deregulation in Acute Leukemia and Implications for Therapy”, Vanderbilt University Department of Biochemistry, Nashville, TN, January 28, 2013. Invited speaker, United States and Canadian Academy of Pathology, Baltimore, MD, March 13, 2013. Invited speaker, 2013 FASEB Summer Research Conference on Hematologic Malignancies, Saxtons River, VT, August 4-9, 2013. LOCAL AND REGIONAL PRESENTATIONS

17

"Mechanisms of Hox Gene Regulation by MLL", Department of Pediatrics, University of Pennsylvania School of Medicine, September 23, 1999. "The role of the mixed lineage leukemia protein (MLL) in Hox gene regulation and hematopoiesis", Division of Hematology/Oncology, Children's Hospital of Philadelphia, January 11, 2000. "Classification of Lymphomas: From NCl Working Formulation to WHO Classification", Current Concepts in Biology, Diagnosis, and Treatment of Lymphomas (University of Pennsylvania Cancer Center), West Conshohocken, PA, April 14, 2000. "Gastric MALT Lymphoma", Current Concepts in Biology, Diagnosis, and Treatment of Lymphomas (University of Pennsylvania Cancer Center), West Conshohocken, Pennsylvania, April 14, 2000. "Classification of Lymphomas: From NCl Working Formulation to WHO Classification", (University of Pennsylvania Cancer Center Ground Rounds) Philadelphia, Pennsylvania, May 3, 2000. "Transcriptional Deregulation by Leukemogenic MLL Fusion Proteins", Hematology-Oncology Research Conference, University of Pennsylvania of Medicine, February 20, 2001. "Transcriptional Deregulation by MLL Fusion Proteins", Stem Cell Biology and Therapeutics Symposium, University of Pennsylvania School of Medicine. (Acute myelogenous leukemia session chair), April 26, 2001. "Transcriptional Deregulation by MLL Fusion Proteins", Pathology Grand Rounds, University of Pennsylvania School of Medicine, June 18, 2001. "AML/MDS and WHO Classification", Leukemia and Myelodysplasia: Advances in Biology, Diagnosis, and Management (University of Pennsylvania Cancer Center), West Conshohocken, Pennsylvania, November 16, 2001. "MLL: Master Editor of the Histone Code", Pathology Grand Rounds, University of Pennsylvania School of Medicine, September 30, 2002. "World Health Organization (WHO) Classification of Lymphomas" Second Biennial Symposium on Biology, Diagnosis and Treatment of Lymphomas (University of Pennsylvania Cancer Center), West Conshohocken, PA, October 4, 2002. "MLL: Master Editor of the Histone Code", Leukemia and Stem Cell Biology Translational Research Group, University of Pennsylvania School of Medicine, October 28, 2002. "MLL: Editor of the Histone Code in Development and Leukemia" John Morgan Society, University of Pennsylvania School of Medicine, June 4, 2003. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, November 20, 2003. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " University of Michigan Medical School, Department of Pathology Research Seminar, September 8, 2005. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " University of Michigan Medical School, Pediatric Hematology/Oncology Conference, September 14, 2005.

18

“Transcriptional Regulation of the Histone Methyltransferase MLL” 4th Annual Pathology Research Symposium, University of Michigan Medical School, November 4, 2005. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " University of Michigan Medical School, Division of Endocrinology Research Seminar, January 5, 2006. "Mechanisms of Transformation by MLL: Insights from Fruit Flies, Mice, and Microarrays " University of Michigan Medical School, Cancer Center Stem Cell Seminar Series, January 12, 2006. “Cancer Genetics” University of Michigan Medical School, Mini-Med Lecture, May 3, 2006. “Epigenetic Dysregulation in Mixed Lineage Leukemia”, University of Michigan Medical School, Division of Pediatric Hematology/Oncology, January 30, 2008. “Mechanisms of Transcriptional Regulation and Transformation by MLL”, University of Michigan Medical School, Department of Pathology Research Seminar, February 21, 2008. “Cancer Genetics” Pioneer High School, Ann Arbor, MI, March 21, 2008. “Identification of New Therapeutic Targets in Leukemia with MLL Rearrangements”, University of Michigan Cancer Center Grand Rounds, Ann Arbor, MI, November 24, 2008. “Epigenetic Dysregulation in Acute Leukemia”, University of Michigan Medical School, Division of Hematology/Oncology, Ann Arbor, MI, July 1, 2009. “AML Diagnosis in the 21st Century”, Frontiers in Diagnostic Pathology (Plenary Speaker), Ann Arbor, MI October 9, 2009. “Toward Targeted Therapy for Acute Leukemia”, Dean’s Lecture Series, University of Michigan Medical School, Ann Arbor, MI, November 17, 2009. “Moving Toward Targeted Therapy for Acute Leukemia”, Department of Pediatrics, University of Michigan Medical School, Ann Arbor MI, January 26, 2011. “Regulation of Myeloid Differentiation and Self Renewal by Hoxa9”, Epigenetics and Chemical Biology Symposium”, Department of Pathology, University of Michigan Medical School, Ann Arbor MI, June 30, 2011. “Personalized Medicine”, University of Michigan Cancer Center, Ann Arbor, MI, January 11, 2012. “Mechanisms of Transformation by HOXA9 and MEIS1” University of Michigan Cancer Biology Program, Ann Arbor MI, January 12, 2012. “An Introduction to Personalized Medicine”, Department of Pathology, University of Michigan, Ann Arbor, MI, January 26, 2012. “Targeted Therapy for Acute Leukemia” Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor MI, January 27, 2012. “Personalized Cancer Diagnostics,” Symposium on Personalized Medicine, University of Michigan School of Dentistry, Ann Arbor MI, March 28, 2012.

19

“Deregulation of HOX Proteins in Acute Leukemia,” Department of Internal Medicine Hematology/Oncology Grand Rounds, University of Michigan School of Dentistry, Ann Arbor MI, March 29, 2012. “Therapeutic Implications of Homeobox Deregulation in Acute Leukemia” University of Michigan Comprehensive Cancer Center Annual Research Symposium, Ann Arbor, MI, November 9, 2012 PATENTS COMPOSITIONS AND METHODS FOR TREATMENT OF LEUKEMIA PCT/US10/47894 Grembecka, J., Cierpicki, T., Hess, J.L. Filed September 3, 2010 Covers two classes of small molecule inhibitors of the MLL-menin interaction for therapeutic purposes BIBLIOGRAPHY

Peer-reviewed publications:

1. Hirsch, R.L., Mokhtarian, F., Griffin, D.E., Brooks, B.R., Hess, J.L., Johnson, R.T.: Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production. Clin Immunol Immunopathol 21:341-350, 1981.

2. Wolinsky, J.S., Waxham, M.N., Hess, J.L., Townsend, J.J., Baringer, J.R.: Immunochemical features of a case of progressive rubella panencephalitis. Clin Exp Immunol 48:359-366, 1982.

3. Narayan, O., Sheffer, D., Griffin, D.E., Clements, H., Hess, J.L.: Lack of neutralizing antibodies to caprine

arthritis-encephalitis virus in persistently infected goats can be overcome by immunization with inactivated mycobacterium tuberculosis. J Virol 49:349-355, 1984.

4. Hess, J.L., Clements, J.E., Narayan, O.: Cis and trans-acting transcriptional regulation of visna virus. Science

229:482-485, 1985.

5. Kennedy, P.G.E., Newsome, D.A., Hess, J.L., Polk, B.F.: Cytomegalovirus but not human T-lymphotropic virus type III/lymphadenopathy associated virus detected by in situ hybridization in patients with the acquired immune deficiency syndrome. Brit Med J 293:162-164, 1986.

6. Griffin, D.E., Hess, J.L.: Cells with natural killer cell activity in the cerebrospinal fluid of normal mice and

athymic nude mice with acute Sindbis virus encephalitis. J Immunol 136:1841-1845, 1986.

7. Hess, J.L., Pyper, J, Clements, J.E.: Nucleotide sequence and transcriptional activity of the caprine arthritis-encephalitis virus long terminal repeat. J Virol 60:385-393, 1986.

8. Small, J., Bierberich, C., Ghotbi, Z., Hess, J.L., Scangos, G., Clements, J.: The visna virus LTR directs

expression of a reporter gene in activated macrophages, lymphocytes, and the CNS of transgenic mice. J Virol 63:1891-1896, 1989.

9. Gabuzda, D.H., Hess, J.L., Small, J.A., Clements, J.E.: Regulation of the visna virus long terminal repeat in

macrophages involves cellular factors which bind sequences containing AP-1 sites. Mol Cell Biol 9:2728-2733, 1989.

20

10. Hess, J.L., Small, J.A., Clements, J.E.: Analysis of sequences in the visna virus long terminal repeat which control transcriptional activity and respond to viral transactivation: Involvement of AP-1 sites in basal activity and transactivation. J Virol 63:3001-3015, 1989.

11. Hess, J.L.: Mutational analysis of the transcriptional control elements in the visna virus long terminal repeat.

Ph.D. Thesis. The Johns Hopkins University, 1989.

12. Shivdasani, R.A., Hess, J.L., Skarin, A.T., Pinkus, G.S.: Intermediate lymphocytic lymphoma: Clinical and pathologic features of a recently characterized subtype of non-Hodgkin’s lymphoma. J Clin Oncol 1993;11:802-811, 1993.

13. Hess, J.L., Bodis, M.D., Pinkus, G., Silver, B., Mauch, P.: Histopathologic grading of nodular sclerosis

Hodgkin’s disease; Lack of prognostic significance in 254 surgically staged patients. Cancer 74:708-714, 1994.

14. Linette, G.P., Hess, J.L., Sentman, C.L., Korsmeyer, S.J.: Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice. Blood 86:1255-1260, 1995.

15. Sires, U.I., Mallory, S.B., Dehner, L.P., Hess, J.L., Keating, J.P., Bloomberg, G.: Cutaneous presentation of

juvenile chronic myelogenous leukemia: a diagnostic and therapeutic dilemma. Ped Dermatol 12:364-368, 1995.

16. Yu, B.Y., Hess, J.L., Horning, S.E., Brown, G., Korsmeyer, S.J.: Hox expression and segment identity are altered in Mll-mutant mice. Nature 378:505-508, 1995.

17. Hess, J.L., Zutter, M., Castleberry, R., Emanuel, P.: Juvenile chronic myelogenous leukemia. Am J Clin Pathol

105:238-248, 1996.

18. Kaleem, Z., Wakoff, A.R., Smith, R.P., Hess, J.L.: Blastic transformation of mantle cell lymphoma. Arch Pathol Lab Med 120:577-580, 1996.

19. Marley, E.F., Liapis, H., Hess, J.L., Dehner, L.P.: Myocardial extramedullary hematopoiesis following

myocardial infarction. Cardiovasc Pathol 5:333-336, 1996.

20. Lin, Y., Govindan, R., Hess, J.L.: Malignant hematopoietic breast tumors. Am J Clin Pathol 107:177-186, 1997.

21. Hess, J.L., Yu, B.D., Li, B., Hanson, R., Korsmeyer, S.J.: Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 90:1799-1806, 1997 (featured on cover).

22. Naughton, M.J., Hess, J.L., Zutter, M.M., Bartlett, N.L.: Bone marrow staging in non-Hodgkin’s lymphoma: Is

flow cytometry a useful test? Cancer 82:1154-1159, 1998.

23. Yu, B.D., Hanson, R., Hess, J.L., Horning, S., Korsmeyer, S.J.: MLL functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci (USA) 95:10632-10636, 1998.

24. Hess, J.L.: Detection of chromosomal translocations in leukemia: Is there a best way? Am J Clin Pathol 109:3-

5, 1998. Hess, J.L.: Chromosomal translocations in benign tumors: The high mobility group (HMGI) proteins. Am J Clin Pathol 109:251-261, 1998.

25. Zutter, M.M., Hess, J.L.: Guidelines for the diagnosis of leukemia and lymphoma in children. Am J Clin Pathol

109 (Suppl 1):S9-S22, 1998.

26. Hess, J.L., Korsmeyer, S.J.: Life, death, and nuclear spots. Nature Genet 20:220-222, 1998.

21

27. Van Dyk, L.F., Hess, J.L., Katz, J.D., Jacoby, M., Speck, S.H., Virgin, H.W.: The murine γ-herpesvirus 68 V-

cyclin is an oncogene that is proproliferative in primary lymphocytes. J Virol 73:5110-5122, 1999.

28. Kaleem, Z., Watson, M.S., Zutter, M.M., Blinder, M.A., Hess, J.L.: Acute promyelocytic leukemia with additional cytogenetic abnormalities and absence of Auer rods. Am J Clin Pathol 112:113-118, 1999.

29. Alvarez, F.V., Olander, J., Crimmins, D., Prieto, B., Pas, A., Alonso, R., Porter, S., Hess, J.L., Christ, R.D.,

Landt, Y., Ladenson, J.H.: Development, characterization, and use of monoclonal antibodies made to antigens expressed on the surface of fetal nucleated red blood cells. Clin Chemistry 45:1614-1620, 1999.

30. Hanson, R.D., Hess, J.L., Yu, B.D., Ernst, P., van Lohuizen, M., Berns, A., van der Lugt, N.M.T., Shashikant,

C.S., Ruddle, F.H., Seto, M. Korsmeyer, S.J.: Mammalian Trithorax and Polycomb homologues are antagonistic regulators of homeotic development. Proc Natl Acad Sci (U.S. A.) 96:14372-14377, 1999.

31. Bodo, I., Peters, M., Radich, J.P., Hess, J.L., Blinder, M., Watson, M.S., Van Rheeden, R., Natarajan, S., Lowell, J.A., Brown, R., DiPersio, J., Adkins, D.: Donor-Derived Acute Promyelocytic Leukemia in a Liver Transplant Recipient. New Engl J Med 341:807-813, 1999.

32. Kraus, M.D., Shenoy, S., Chatila, T., Hess, J.L.: A light microscopic, immunophenotypic and molecular genetic

study of autoimmune lymphoproliferative syndrome caused by fas mutation. Ped Dev Pathol 3:101-109, 2000.

33. Khariwhala, S.S., Litman, D., McQuone, S.J., Hess, J.L., Thaler, E.R.: Quiz Case 2. Arch Otolaryngol: Head and Neck Surgery 126:1391-1393, 2000.

34. Caslini, C., Shilatifard, A., Yang, L., Hess, J.L.: The amino terminus of the mixed lineage leukemia (MLL)

protein promotes cell cycle arrest and monocytic differentiation. Proc Natl Acad Sci (U.S.A.) 97:2797-2802, 2000.

35. Thorson, P., Hess, J.L.: Transformation of monocytoid B-cell lymphoma to large cell lymphoma associated with

crystal storing histiocytes. Arch Pathol Lab Med 124:460-462, 2000.

36. Zhang, T., Westervelt, P, Hess, J.L.: Pathologic, cytogenetic, and molecular assessment of acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (As2O3). Mod Pathol 13:954-961, 2000.

37. Caslini, C., Alarcòn, A.S., Hess, J.L., Tanaka, R., Murti, G., Biondi, A.: The amino terminus targets the mixed

lineage leukemia (MLL) protein to the nucleolus, nuclear matrix, and mitotic chromosomal scaffolds. Leukemia 14:1898-1908, 2000.

38. DiMartino, J.F., Miller, T., Ayton, P.M., Landewe, T., Hess, J.L., Cleary, M.L., Shilatifard A,: A carboxyl-

terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 96:3887-3893, 2000.

39. Movsas, T.Z., Balcer, L.J., Eggenberger, E.R., Hess, J.L., Galetta, S.L.: Sixth nerve palsy as a presenting sign of

intracranial plasmacytoma and multiple myeloma. J. Neuro-Opthalmology 20:242-245, 2000.

40. Portis, T., Grossman, W.J., Harding, J.C., Hess, J.L., Ratner, L.: Analysis of p53 inactivation in a human T-cell leukemia virus type 2 Tax transgenic mouse model. J Virol 75:2185-2193, 2001.

41. Wang, Y.L., Bagg, A., Pear, W,, Nowell, P.C., Hess, J.L.: Chronic Myelogenous leukemia: Laboratory

diagnosis and monitoring. Genes Chrom Cancer 32:97-111, 2001.

22

42. Hess, J.L., Kossev, P.: Molecular genetics of benign tumors. Cancer Invest 20:1-11, 2002.

43. Hess, J.L.: The advent of targeted therapeutics and implications for pathologists. Am J Clin Pathol 117:355-357,

2002.

44. Milne, T.A., Briggs, S.D., Brock, H.W., Martin, M.E., Gibbs, D., Allis, C.D., Hess, J.L.: MLL targets SET domain methyltransferase activity to Hox gene promoters. Molecular Cell 10:1107-1117, 2002.

45. Hess, J.L.: The Cancer Genome Anatomy Project: Power Tools for Cancer Biologists. Cancer Invest 21:325-

326, 2003.

46. Martin, M.E., Milne T.A., Bloyer, S., Galoian, K., Shen, W., Gibbs, D., Brock, H.W., Slany, R., Hess, J.L.: Dimerization of MLL fusion proteins immortalizes hematopoietic cells. Cancer Cell 4: 197-207, 2003 (featured as Immediate Early Publication August 25, 2003).

47. Zeisig, B.B., Milne T., García-Cuéllar, M.P., Schreiner, S., Martin, M.E., Fuchs, U., Chanda, S., Walker, J., Soden,

R., Hess, J.L., Slany R.K. Hox a9 and Meis1 are key targets for MLL-ENL mediated cellular immortalization. Mol Cell Biol 24:617-628, 2004.

48. Hughes, C.M., Rozenblatt-Rosen, O., Milne, T.A., Copeland, T.D., Levine, S., Lee, J.C., H Hayes, N.,

Shanmugam, K.S., Bhattacharjee, Biondi, C.A., Kay, G.F., Hayward, N.K., Hess, J.L., Meyerson, M.: Menin associates with a trithorax family histone methyltransferase complex and with the Hox c8 locus. Molecular Cell 13:587-597, 2004.

49. Mitra-Kaushik, S., Hess, J.L., Ratner, L.: Effects of the proteosome inhibitor PS-341 on tumor growth in HTLV-

1 tax transgenic mice and tax tumor transplants. Blood 104:802-809, 2004 (online publication April 15, 2004).

50. Mitra-Kaushik, S., Harding, J., Hess, J.L., Schreiber, R., Ratner, L.: Enhanced tumorigenesis in HTLV-1 tax transgenic mice deficient in interferon gamma. Blood 104:3305-11, 2004 (online publication August 3, 2004).

51. Hess, J.L.: MLL, Hox genes, and leukemia: the plot thickens. Blood 103:2870-2871, 2004.

52. Hess, J.L.: MLL, a histone methyltransferase disrupted in leukemia. Trends in Molecular Medicine 10:500-7,

2004.

53. Hess, J.L.: Mechanisms of transcriptional regulation by MLL. Critical Reviews in Eukaryotic Gene Regulation 14:235-254, 2004.

54. Hess, J.L. and Hug, B. Fusion-protein truncation provides new insights into leukemogenesis. Proc Natl Acad Sci

(U.S.A.) 101:16985-6, 2004.

55. Hess, J.L.: Stanley J. Korsmeyer 1950-2005. Nat Cell Biol 7(6):556, 2005.

56. Milne, T.A., Hughes, C.M., Lloyd, R., Yang, Z., Rozenblatt-Rosen O., Dou, Y., Schnepp, R., Krankel, C., Livolsi, V.A., Gibbs, D., Hua, X., Roeder, R.G., Meyerson, M., Hess, J.L.: Menin and MLL cooperatively regulate cyclin-dependent kinase inhibitor expression. Proc Natl Acad Sci (U.S.A.) 102:749-754, 2005 (online publication January 7, 2005).

57. Wang, J., Iwasaki, H., Krivtsov, A., Febbo, P.G., Thorner, A.R., Ernst, P., Anastasiadou, E., Kutok, J.L., Kogan,

S.C., Zinkel, S.S., Fisher, J.K., Hess, J.L., Golub, T.R., Armstrong, S.A., Akashi, K., Korsmeyer, S.J.:

23

Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J. 24:368-81, 2005 (online publication January 6, 2005).

58. Zeisig, D.T., Bittner, C.B., Zeisig, B.B., García-Cuéllar, M. -P., Hess, J.L., Slany, R.K.: The eleven-nineteen

leukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 24(35):5525-32, 2005 (online publication April 25, 2005).

59. Dou, Y., Milne, T.A., Tackette, A.J., Smith, E.R., Fukuda, A., Wysocka, J., Allis, C.D., Chait, B.T., Hess, J.L.,

Roeder, R.G.: Physical Association and Coordinate Function of the H3 K4 Methyltransferase MLL1 and the H4 K16 Acetyltransferase MOF. Cell 121:873-885, 2005.

60. Milne, T.A., Dou, Y., Martin, M.E., Brock, H.W., Roeder, R.G., Hess, J.L.: MLL associates specifically with a

subset of transcriptionally active target genes. Proc Natl Acad Sci (U.S.A.) 102(41):14765-14770, 2005 (featured on cover and subject of a review).

61. Tarakonova, V.L., Suarez, F., Jacoby, M.A., Tibbetts, S.A., Weck, K.E., Hess, J.L., Speck, S.H., Virgin IV,

H.W.: Association of Murine γHerpesvirus 68 with Lymphoproliferative Disorders in β2 microglobulin deficient mice. J Virology 79:14668-14679, 2005.

62. Milne, T.A., Martin, M.E., Allman, D., Brock, H.W., Slany, R.K., Hess, J.L.: Leukemogenic MLL Fusion

Proteins Bind across a Broad Region of the Hox a9 Locus, Promoting Transcription and Multiple Histone Modifications. Cancer Res 65:11367-11374, 2005.

63. Chen, Y., Yan, J., Keeshan, K., Tubbs, A.T., Wang, H., Silva, A., Brown, E.J., Hess, J.L., Pear, W.S., Hua, X.:

The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci (U.S.A.) 103:1018-1023, 2006.

64. Hess, J.L., Bittner, C.B., Zeisig, D.T., Bach, C., Fuchs, U., Borkhardt, A., Frampton, J., Slany, R.K.: c-Myb is an

essential downstream target for homeobox mediated transformation of hematopoietic cells. Blood 108:297-304, 2006.

65. Sitwala, K.V., Hess, J.L. Structural basis of multimer-mediated mayhem. Cancer Cell 9:241-242, 2006.

66. Crawford, B., Hess, J.L. MLL core components give the green light to histone methylation. ACS Chemical

Biology 1:495-498, 2006.

67. Caslini, C., Yang, Z.H., Milne, T.A., Slany, R.K., Hess, J.L. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res. 67:7275-7283, 2007.

68. Mueller, D., Bach., C, Zeisig, D., Garcia-Cueller, M.-P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A.,

Chinnaiyan, A., Hess, J.L., Slany, R.K. A Role for the MLL Fusion Partner ENL in Transcriptional Elongation and Chromatin Modification. Blood 110:4445-54, 2007.

69. Muntean, A.G., Giannola, D., Udager, A., Hess, J.L. The PHD fingers of MLL block MLL fusion protein-

mediated transformation. Blood 112:4690-93, 2008.

70. Dou, Y, Hess, J.L., Mechanisms of Transcriptional Deregulation by MLL and its Disruption in Acute Leukemia. Int Journal of Hematol Jan 87:10-8, 2008.

71. Sitwala, K.V., Dandekar, M.N., Hess, J.L. Hox proteins and leukemia. Intl J Clin and Exp Path 1:461-74, 2008.

24

72. Muntean, A., Hess, J.L. MLL-AF9 induced leukemia: Hardwired or taking cues from the microenvironment? Cancer Cell 13:46507, 2008.

73. Milne, T.A., Zhao, K., Hess, J.L. Chromatin Immunoprecipitation for Analysis of Histone Modifications and

Chromatin-Associated Proteins. Mol Biol 538:409-423, 2009.

74. Hess, J.L. What Hematopathology tells us about the Future of Pathology Informatics. Arch Path Lab Med 133:908-11, 2009.

75. Caslini, C., Connelly, J.A., Serna, A., Broccoli, D., Hess, J.L. MLL associates with telomeres and regulates

telomeric repeat-containing RNA transcription. Mol Cell Biol, 29:4519-26, 2009. (Epub 2009 Jun 15).

76. Muntean, A.G., Hess, J.L. Epigenetic Dysregulation in Cancer. Am J Pathol 175:1353-61, 2009 (Epub 2009 Aug 28).

77. Fisher, C.L., Pineault, N., Brookes, C., Helgason, C.D., Ohta, H., Bodner, C., Hess, J.L., Humphries, R.K.,

Brock, H.W. Loss-of-function Additional sex combs-like1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 115:38-46, 2010 (Epub 2009 Oct 27).

78. Fisher, C.L., Lee, I., Komljenovic, I., Bloyer, S., Bozza, S., Chevalier, J., Dahl, A., Bodner, C., Helgason, C.D.,

Hess, J.L., Brock, H. Additional sex combs-like1 belongs to the enhancer of Trithorax and Polycomb Group and genetically interacts with Cbx2 in mice. Dev Biol 337:9-15, 2010 (Epub 2009 Oct 13).

79. Maillard, I. Hess, J.L., The role of menin in hematopoiesis. Adv Exp Med Biol 668:51-7, 2009.

80. Muntean, A.G., Tan, J., Sitwala, K., Huang, Y., Bronstein, J., Connelly, J.A., Basrur, V., Elenitoba-Johnson,

K.S.J., Hess, J.L. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 17: 609-21, 2010 (immediate online publication June 9, 2010, subject of a Cancer Cell Preview and Nature Reviews Cancer review).

81. Monroe, S.C., Jo, S.Y., Sanders, D.S., Basrur, V., Elenitoba-Johnson, K.S., Slany, R.K., Hess, J.L. MLL-AF9

and MLL-ENL alters the dynamic association of transcriptional regulators with genes critical for leukemia Exp Hematol 39:1424-6, 2011 (published online September 17, 2010).

82. Hess, J.L. Pathologists in the 21st Century: What are we anyway? Arch Path Lab Med 134:1424-6, 2010.

83. Betz B., Hess, J.L. AML Diagnosis in the 21st Century. Arch Path Lab Med 134:1427-33, 2010.

84. Sanders, D., Muntean, A., Hess, J.L. Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias? Leukemia

Research 35:299-300, 2011 (published online October 15, 2010).

85. Tan J., Muntean, A.G. Hess, J.L. PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget 1:461-5, 2010 (published October 2010, www.impactjournals.com/oncotarget).

86. Jo,S.Y., Granowicz, E.M., Maillard., Thomas, D., Hess J.L. Requirement for Dot1l in postnatal hematopoiesis

and leukemogenesis by MLL translocation Blood 117:4759-4768, 2011 (published online February 25, 2011). 87. Muntean, A.G., Hess, J.L. Pathogenesis of MLL-associated leukemia Ann Rev Pathol (published online January

25, 2011).

25

88. Tan, J., Jones, M., Koseki, H., Nakayma, M., Muntean, A., Maillard, I., Hess J.L. CBX8, a Polycomb Group protein, is essential for MLL-AF9 oncogenic transformation Cancer Cell 20:563-75, 2011 (Featured Article and subject of a Preview).

89. Huang, Y.S., Sitwala, K., Bronstein, J., Sanders, D. Dandekar, M., Robertson, G. MacDonald, J., Cezard, T.,

Bilenky, N., Zhao, Y., Zeng, T., Hirst, M., Hero, A., Jones, S., Hess J.L. Hoxa9 and Meis1 interact with myeloid-specific enhancers in hematopoietic cells Blood (published online November 9, 2011)(highlighted in Faculty of 1000).

90. Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A., Sorenson, R.J., Showalter, H., Murai, M., Amalia, B.,

Hartley, T., Hess, J.L., Cierpicki, T. Small molecule inhibitors of Menin-MLL interaction reverse oncogenic activity of MLL fusion proteins: potential targeted therapy for MLL leukemias Nature Chem Biol 8:277-84, 2012 (subject of a Nature Reviews Cancer Review).

91. Wang, J., Muntean, A.G., Hess, J.L. ECSASB2 mediates MLL degradation and regulates hematopoietic

differentiation Blood 119:1151-61, 2012 (published online December 15, 2011).

92. Altuna, A., Garrett-Bakelman, F.E., Kormaksson, M., Busuttil, J., Zhang, L., Khrebtukova, I., Valk, P.J.M., Lowenberg, B. Delwel, R., Fernandez, H.F., Paietta, E., Tallman, M.S., Schroth, G., Mason, C. Huang, Y., Hess, J.L., Melnick, A., Figueroa M.E. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genetics 8 e1002781, 2012(published online June 21, 2012).

93. Tomlins, S.A., Penny, R.J., Hess J.: 21st Century Signout in Pathology. Clinics Lab Med 32:639-50, 2012.

94. Wang, J., Muntean, A.G., Wu, L., Hess, J.L. A subset of mixed lineage leukemia proteins have E3 ligase activity.

J Biol Chem 287:43410-6, 2012 (published online November 5, 2012).

95. Maethner, E., Garcia-Cueller, M.-P., Breitinger, C., Takacova, S., Hess, J.L. Slany, R.K. MLL-ENL inhibits Polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells (submitted).

96. Muntean, A., Granowicz, E. Hess, J.L. Disruption of the MLL-PAFc interaction selectively inhibits

transformation by MLL fusion proteins (submitted).

97. Cao, F., Townsend, E.C., Karatas, H., Li, L., Chen, Y., Quillette, P., Hess, J.L., Lei, M., Malek, S., Qin, Z., Wang, S., Dou, Y. Targeting H3K4 methylation for treatment of mixed lineage leukemia (submitted).

98. Shen C., Jo S.Y., Cierpicki T., Hess J.L., Nikolovska-Coleska Z. Targeting DOT1L recruitment. Biochemical and

functional characterization of AF9/ENL-DOT1L Protein-Protein Interaction between DOT1L and MLL-fusion proteins (submitted).

99. Collins, C., Hess, J.L. The role of HOX genes in leukemia Oncogene (invited review, in preparation).

100. Huang, Y., Robertson, G. Bronstein, J., Sanders, D., Sitwala, K., Hero, A., Hess, J.L. Spatial distribution-

based inference of protein interaction using high-throughput sequencing (in preparation). 101. Crawley, M., Keshock, M., Wheat, G., Hess, J.L., Hutton D. Cost effectiveness analysis of crizotinib for relapsed non-small cell lung cancer (in preparation). Abstracts (since 2000):

26

1. Galoian, K., Milne, T., Brock, H., Shilatifard, A., Hess, J.L.: Deregulation of c-MYC by leukemogenic MLL fusion proteins. Blood 96 (Suppl. 1): 457A, 2000. (Presented at the American Society of Hematology, San Francisco, 2000).

2. Milne, T., Brock, H.R., Hanson, R.D., Gibbs, D., Hess, J.L.: MLL controls histone acetylation and H3 lysine 4 methylation at the Hox c8 locus. Proceedings of 12th IMP Spring Conference, pg. 37. (Presented at 12th Annual IMP Conference “Epigenetic Programming of the Genome”, Vienna, Austria, 2002).

3. Martin, M.E., Milne, T., Galoian, K., Gibbs, D., Slany, R ,Brock, H. and Hess, J.L.: Dimerization of MLL

transforms by reversibly blocking myeloid differentiation. Blood 100 (Suppl. 1): 528A, 2002 (Presented at American Society of Hematology, Philadelphia, 2002).

4. Milne, T., Briggs, S., Brock, H.W., Gibbs, D., Allis, C.D., and Hess, J.L.: The mixed lineage leukemia protein

MLL targets SET domain methyltransferase activity to Hox gene promoters. Blood 100 (Suppl. 1): 137A, 2002 (Presented at American Society of Hematology, Philadelphia, 2002).

5. Martin, M.E., Milne, T., Bloyer, S., Galoian, K., Shen, W., Gibbs, D., Brock, H., Slany, R , and Hess, J.L.

Dimerization dependent and independent pathways for MLL mediated leukemogenesis. Blood 102 (Suppl. 1): 849A, 2003 (presented at American Society of Hematology, San Diego, 2003).

6. Zeisig, B.B., Milne T., García-Cuéllar, M.P., Schreiner, S., Martin, M.E., Fuchs, U., Chanda, S., Walker, J.,

Soden, R., Hess, J.L., Slany R.K. Hox a9 and Meis1 are key targets for MLL-ENL mediated cellular immortalization. Blood 102 (Suppl. 1): 170A, 2003 (presented at American Society of Hematology, San Diego, 2003).

7. Kumar, A.R., Slany, R.K., Hess, J.L., Kersey, J.H. MLL-AF9 and MLL-ENL induce deregulation of similar

downstream candidate genes: an analysis across experimental protocols and laboratories. Blood 104 (Suppl. 1): 114A, 2004 (presented at American Society of Hematology, San Diego, 2004).

8. Milne, T.A., Martin, M.E., Slany, R.K., Hess, J.L. Leukemogenic MLL fusion proteins promote MLL association

with Hox loci. Blood 104 (Suppl. 1): 920A, 2004 (presented at American Society of Hematology, San Diego, 2004).

9. Hess, J.L., Yang, Z., Wang, H., Chen, Y., Milne, T.A., Martin, M.E., Slany, R.K., Hua, X. Interaction of MLL

amino terminal sequences with menin is required for transformation. Blood 106 (Suppl. 1): 196A, 2005. (presented at American Society of Hematology, Atlanta, GA 2005).

10. Slany, R.K., Bittner, C.B., Zeisig, D.T., Bach, C., Hess, J.L. c-Myb is an essential downstream target for

homeobox mediated transformation of hematopoietic cells. Blood 106 (Suppl. 1): 196A-197A, 2005. (presented at American Society of Hematology, Atlanta, GA 2005).

11. Slany, R.K., Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M.P., Monroe, S., Sreekumar, A., Zhao, R.,

Nesvizhskii, A., Chinnaiyan, A., Hess, J.L. Purification of an MLL partner associated complex (MPAC) suggests a common role for MLL fusion partners in transcriptional elongation. Blood 108 (11): 231a, 2006.

12. Caslini, C, Hess, JL. MLL modulates telomere length in mammalian cells. Blood 108(11): 626a, 2006. (Presented

at American Society of Hematology, Orlando, FL 2006). 13. Muntean, AG, Hess, J.L. The MLL PHD Fingers block MLL Fusion Protein Mediated Transformation. American Society of Hematology, December 8-10, 2007.

27

14. Sitwala, KV, MacDonald, JW, Giannola, DM, Hess, J.L. Identification of Hoxa9 targets in myeloid progenitors using conditional expression . American Society of Hematology, December 8-10, 2007. 15. Wing, A, Hess, J.L. Quantitative cost-benefit analysis on co-locating research labs with clinical facilities.

Tradeline, San Diego, CA, December 3-4, 2007.

16. Caslini, C., Serna, A., Fidanza, V., Hess, J.L. MLL regulates telomere length and initiation of replicative senescence in mammalian cells. Keystone Symposium: Cell Death & Senescence, Breckenridge, CO, February 7-12, 2008.

17. Monroe, S., Jo, S.Y., Basrur, V., Elenitoba-Johnson, K.S., Slany, R.K., Hess, J.L. Identification and

Characterization of an MLL Fusion Partner-associated Complex: MPAC. American Association for Cancer Research, Cancer Epigenetics, Boston, MA, May 28-31, 2008.

18. Hess, J.L. Epigenetic Dysregulation in Mixed Lineage Leukemia. Molecular Mechanisms of Normal and

Malignant Hematopoiesis, Sonder forschungsbereich 684, Munich, Germany, April 23, 2009.

19. Muntean, A., Tan, J., Sitwala, K., Monroe, S., Dandekar, M., Huang, Y., Robertson, G., Hero, A., Hess, J.L. Mechanisms of Transformation by MLL Fusion Proteins. FASEB Summer Research Conference on Hematologic Malignancies. Saxtons River, VT, August 2-7, 2009.

20. Muntean, A.G. Tan, J., Basrur, V. Elenitoba-Johnson K.S.J., Hess J.L. The PAF complex synergizes with MLL

fusion proteins at Hox loci to promote leukemogenesis. Blood 114:1277a, 2009 (presented at American Society of Hematology, New Orleans, LA, December 5-8, 2009).

21. Tan, J., Muntean, A.G., Basrur, V., Elenitoba-Johnson, K., Hess, J.L. The PAF complex synergizes with MLL

fusion proteins at Hox loci to promote leukemogenesis. Keystone Symposia on Molecular Basis for Chromatin Structure and Regulation, Taos, New Mexico, Jan. 17-20, 2010.

22. Tan, J. and Hess, J.L., CBX8, a Polycomb-group protein, is essential for MLL-AF9-induced leukemogenesis.

Blood 116:327a, 2010 (presented at the Annual Meeting of the American Society of Hematology, Orange County, FL, December 4-7, 2010).

23. Wang, J., Muntean, A. and Hess J.L. A novel ubiquitination pathway regulates MLL activity during

hematopoiesis. Blood 116:1698a, 2010 (presented at Annual Meeting of the American Society of Hematology, Orange County, FL, December 4-7, 2010).

24. Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A., Sorenson, R., Showalterm H., Hess J.L., Cierpicki, T. /a

strategy to develop potent inhibitors of protein-protein interaction: targeting menin-MLL interaction in leukemia (presented at Keystone Symposia: Evolving Approaches to Early Stage Drug Discovery. Snowbird, UT, April 3-7, 2011).

25. Jo, S., Granowicz, E., and Hess J.L. Assessment of DOT1L as a therapeutic target in acute leukemia. Blood

116:1348a, 2010 (presented at the Annual Meeting of the American Society of Hematology, Orange County, FL, December 4-7, 2010).

26. Muntean, A.G., Eric Ranowicz and Hess J.L. Selective inhibition of MLL fusion protein-driven AML by

disruption of MLL-PAFc interaction. (presented at FASEB Summer Research Conference on Hematologic Malignancies. Saxtons River, VT, August 1-4, 2011).

28

27. Developing therapeutic strategies targeting DOT1L in MLL rearranged leukemia, Gibbon, G., Shen, C., Muntean, A., Jo, S., Hess, J.L., Nikolovska-Coleska, Z. (presented at FASEB Summer Research Conference on Hematologic Malignancies. Saxtons River, VT, August 1-4, 2011).

28. Tan, J., Jones, M., Koseki, H., Nakayama, M., Maillard, I., and Hess, J.L. CBX8, a Polycomb-group protein, is

critical for MLL-AF9-induced leukemogenesis (presented at FASEB Summer Research Conference on Hematologic Malignancies. Saxtons River, VT, August 1-4, 2011).

29. Wang, J., Muntean, A.G. and Hess, J.L. ECSASB2 mediates MLL degradation and regulates hematopoietic

differentiation (presented at FASEB Summer Research Conference on Hematologic Malignancies. Saxtons River, VT, August 1-4, 2011).

30. Collins, C. T., Huang, Y., Sanders, D., Bronstein, J. and Hess, J.L. Mechanisms of transformation by Hoxa9 and

Meis1 (presented at FASEB Summer Research Conference on Hematologic Malignancies. Saxtons River, VT, August 1-4, 2011).

31. Muntean, A.G., Granowicz, E.M. and Hess, J.L. MLL fusion protein-driven AML is selectively inhibited by

disruption of the MLL-PAFc interaction (presented at the Annual Meeting of the American Society of Hematology, San Diego, CA, December 9-12, 2011).

32. Grembecka, J., He, S., Shi, A., Rurohit, T., Muntean, A., Li, X., Hartley, T., Sun, D. Hess, J.L. and Cierpicki, T.

Targeting Menin-MLL interactions to inhibit MLL fusion protein oncoproteins in leukemia. (presented at the Annual Meeting of the American Society of Hematology, San Diego, CA, December 9-12, 2011).

33. Maethner, E., Breitinger, C., Garcia-Cueller, M.-P., Hess, J.L. and Slany, R.K. MLL-ENL inhibits Polycomb

repressive complex 1 to achieve efficient transformation of hematopoietic cells. (presented at the Annual Meeting of the American Society of Hematology, San Diego, CA, December 9-12, 2011).

34. Collins, C., Bronstein, J., Sun, J., Nagaraja, S., Hess, J.L. Mechanisms of transcriptional regulation and

transformation by HOXA9 (presented at 9th International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, University of Cincinnati, Cincinnati, OH, May 6-9, 2012).

35. Collins, C., Bronstein, J., Sun, J., Nagaraja, S., Hess J.L. Mechanisms of transcriptional regulation and

transformation by HOXA9 (presented at Scientific Committee on Myeloid Biology, 2012 American Society of Hematology Annual Meeting, Atlanta, GA, December 8-12, 2012).

36. Collins, C., Wang, J., Bronstein, J., Hess, J.L. C/ebpα and Pu.1 are members of a critical regulatory network

required for Hoxa9-mediated immortalization (presented at 2012 American Society of Hematology Annual Meeting, Atlanta, GA, December 8-12, 2012).

37. Wang, J., Collins, C., Nagaraja, J., Bronstein, J. Hess, J.L. Genome-wide analysis identifies novel Hox-regulated

enhanceosomes in hematopoietic cells (presented at Keystone Meeting on Cellular and Molecular Biology, Hematopoiesis, Steamboat Springs, CO, January 14-19, 2013).

38. Hess, J.L. “The Role of the MLL-PAFc Axis in Hematopoiesis and Leukemia” (presented at 6th Biennial

Workshop on the Clinical Translation of Epigenetics in Cancer Therapy, Ashville, NC, January 18-21, 2013). Electronic Publications:

1. Hess, J.L.: Juvenile chronic myelogenous leukemia (JCML). Atlas Genet Cytogenet Oncol Haematol. December 2000. URL: http://www.infobiogen.fr/services/chromcancer/Anomalies/JCML.html (electronic media).

29

2. Hess, J.L., Huret, J.L.: MLL (myeloid/lymphoid or mixed lineage leukemia). Atlas Genet Cytogenet Oncol

Haematol. December 2000. URL: http://www.infobiogen.fr/services/chromcancer/Genes/MLL.html (electronic media).

3. Hess, J.L.: Familial monosomy 7 syndrome. Atlas Genet Cytogenet Oncol Haematol. July 2001. URL:

http://www.infobiogen.fr/services/chromcancer/Kprone/FamilMono7.html (electronic media).

4. Hess, J.L.: Chronic Myelomonocytic leukemia. Atlas Genet Cytogenet Oncol Haematol. July 2001. URL: http://www.infobiogen.fr/services/chromcancer/Anomalies/CMM.html (electronic media).

5. Hess, J.L.: t(1;3)(p36;q21). Atlas Genet Cytogenet Oncol Haematol May 2002. URL:

http://www.infobiogen.fr/services/chromcancer/Anomalies/t(1;3)(p36;q21).html (electronic media).

6. Hess, J.L.: Congenital neutropenia. Atlas Genet Cytogenet Oncol Haematol May 2002. URL: http://www.infobiogen.fr/services/chromcancer/Kprone/CongenitNeutro.html (electronic media).

7. Hess, J.L., Huret, J.L.: ELL (eleven nineteen leukemia). Atlas Genet Cytogenet Oncol Haematol. February

2003. URL: http://www.infobiogen.fr/services/chromcancer/Genes/ELL.html (electronic media).

8. Hess, J.L.: MLL: Deep Insight. Atlas Genet Cytogenet Oncol Haematol, Jan 2006. URL: www.infobiogen.fr/services/chromcancer/Genes/Deep/MLLdeepID20005.html electronic media

Book Chapters:

1. Griffin, D.E., Hess, J.L., Mokhtarian, F.: Entry of proteins and cells into the normal and virus-infected central nervous system. In Behan, P.O., Spreafico, F., eds.: Serona Foundation Symposium, Vol. 12, Neuroimmunology. New York: Raven Press, 1984, pp. 193-206.

2. Hess, J.L., Clements, J.E., Narayan, O.: Cis- and trans-acting transcriptional regulation of visna virus. In Kulstad, R., ed.: AIDS. Washington, D.C.: American Association for the Advancement of Science, 1986, pp. 571-579.

3. Griffin, D.E., Moench, T.R., Hess, J.L., Johnson, R.T.: Cerebrospinal fluid changes in acute viral encephalitis.

In Lowenthal, A., Raus, J., eds.: Cellular and Humoral Components of CSF in Multiple Sclerosis. London: Plenum Publishing Corporation, 1987, pp. 361-367.

4. Clements, J.E., Davis, J., Hess, J.L., Small, J.: Viral and cellular factors which activate in trans the visna virus LTR. In Franza, B.R., Cullen, B.R., Wong-Staal, F., eds.: The Control of Human Retrovirus Gene Expression. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory, 1988, pp. 291-302.

5. Kennedy, P.G.E., Narayan, O., Zink, M.C., Hess, J.L., Clements, J., Adams, R.J.: The pathogenesis of visna, a

lentivirus-induced immunopathologic disease of the central nervous system. In Gilden, D.H., Lipton, H.L., eds.: Clinical and Molecular Aspects of Neurotropic Virus Expression. Boston: Kluwer Academic Publishers, 1989, pp. 393-421.

6. Kraus, M.D., Hess, J.L., Zutter, M.M.: Lymph nodes, spleen, thymus. In: Stocker, J.T., Dehner, L.P., ed:

Pediatric Pathology, Second Edition. Philadelphia, Lippincott 2001, pp.1095-1134.

30

7. Choi, J.K., Hess, J.L. Blood and Marrow Morphology. In Young, N.S., Gerson, S.L., High, K.A. Eds. Clinical Hematology. Philadelphia, Elsevier 2006, pp. 1290-1309.

8. Maillard, I, Hess, J.L. The role of menin in hematopoiesis, K. Balogh and A Patocs, Eds. In Molecular

Mechanisms of MEN1 syndrome, Adv Exp Med Biol, 2009, pp. 51-7.